Website
News25/Ratings0
News · 26 weeks30-60%
2025-10-262026-04-19
Mix1290d
- Insider6(50%)
- SEC Filings4(33%)
- Other2(17%)
Latest news
25 items- SECRafael Holdings Inc. filed SEC Form 8-K: Regulation FD Disclosure, Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits8-K - Rafael Holdings, Inc. (0001713863) (Filer)
- PRRafael Holdings Announces Patent Licensing Agreement with MIT for "Small Molecules to Improve Myelination in ApoE4 positive Alzheimer's Disease"NEWARK, N.J., April 22, 2026 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE:RFL) today announced that its subsidiary, Cyclo Therapeutics, has entered into an exclusive licensing agreement with Massachusetts Institute of Technology ("MIT") covering U.S. Patent No.12285440. This license covers the use of cyclodextrins in patients with Alzheimer's Disease (AD) who carry an ApoE4 genetic mutation, strengthening the company's intellectual property portfolio around Trappsol® Cyclo™ in this important AD patient population. The ApoE4 gene variant is estimated to be present in 50-70% of patients with AD and is believed to be a key risk factor in the development early onset sporadic AD. Dysregulat
- INSIDERSEC Form 4 filed by Polinsky David4 - Rafael Holdings, Inc. (0001713863) (Issuer)
- INSIDERExec Chairman, CEO & President Jonas Howard S covered exercise/tax liability with 9,826 units of Class B Common Stock, decreasing direct ownership by 3% to 323,014 units (SEC Form 4)4 - Rafael Holdings, Inc. (0001713863) (Issuer)
- SECSEC Form 10-Q filed by Rafael Holdings Inc.10-Q - Rafael Holdings, Inc. (0001713863) (Filer)
- SECRafael Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Rafael Holdings, Inc. (0001713863) (Filer)
- PRRafael Holdings Reports Second Quarter Fiscal 2026 Financial ResultsNEWARK, N.J., March 16, 2026 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE:RFL) today reported its financial results for the second quarter fiscal year 2026 ended January 31, 2026. "We remain pleased with the progress of our pivotal Phase 3 TransportNPC™ study evaluating Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease Type C1, which the Data Monitoring Committee (DMC) recommended continuing after their review of prespecified safety and efficacy data at 48 weeks. We believe that Trappsol® Cyclo™ could provide an important new treatment option for patients suffering from this rare and fatal genetic disease," said Howard Jonas, Chief Executive Officer, Executive Chairman and Cha
- INSIDERDirector Sieger Markus was granted 29,528 units of Class B Common Stock, increasing direct ownership by 16% to 219,710 units (SEC Form 4)4 - Rafael Holdings, Inc. (0001713863) (Issuer)
- INSIDERDirector Weiss Michael J was granted 39,370 units of Class B Common Stock, increasing direct ownership by 38% to 141,861 units (SEC Form 4)4 - Rafael Holdings, Inc. (0001713863) (Issuer)
- INSIDERDirector Stein Mark N was granted 39,370 units of Class B Common Stock, increasing direct ownership by 343% to 50,845 units (SEC Form 4)4 - Rafael Holdings, Inc. (0001713863) (Issuer)
- INSIDERDirector Grayson Alan was granted 6,562 units of Class B Common Stock (SEC Form 4)4 - Rafael Holdings, Inc. (0001713863) (Issuer)
- SECSEC Form S-8 filed by Rafael Holdings Inc.S-8 - Rafael Holdings, Inc. (0001713863) (Filer)
- INSIDERExec Chairman, CEO & President Jonas Howard S was granted 75,000 units of Class B Common Stock, increasing direct ownership by 29% to 332,840 units (SEC Form 4)4 - Rafael Holdings, Inc. (0001713863) (Issuer)
- INSIDERChief Financial Officer Polinsky David covered exercise/tax liability with 4,865 units of Class B Common Stock and was granted 50,000 units of Class B Common Stock, increasing direct ownership by 17% to 303,815 units (SEC Form 4)4 - Rafael Holdings, Inc. (0001713863) (Issuer)
- SECRafael Holdings Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - Rafael Holdings, Inc. (0001713863) (Filer)
- INSIDERChief Financial Officer Polinsky David covered exercise/tax liability with 1,961 units of Class B Common Stock, decreasing direct ownership by 0.75% to 258,680 units (SEC Form 4)4 - Rafael Holdings, Inc. (0001713863) (Issuer)
- INSIDERExec Chairman, CEO & President Jonas Howard S covered exercise/tax liability with 9,867 units of Class B Common Stock, decreasing direct ownership by 4% to 257,840 units (SEC Form 4)4 - Rafael Holdings, Inc. (0001713863) (Issuer)
- SECSEC Form 10-Q filed by Rafael Holdings Inc.10-Q - Rafael Holdings, Inc. (0001713863) (Filer)
- SECRafael Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Rafael Holdings, Inc. (0001713863) (Filer)
- PRRafael Holdings Reports First Quarter Fiscal 2026 Financial ResultsNEWARK, N.J., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE:RFL) today reported its financial results for the first quarter fiscal year 2026 ended October 31, 2025. "We remain pleased with the progress of our pivotal Phase 3 TransportNPC™ study evaluating Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease Type C1, which the Data Monitoring Committee (DMC) recommended continuing after their review of prespecified safety and efficacy data at 48 weeks. We believe that Trappsol® Cyclo™ could provide an important new treatment option for patients suffering from this rare and fatal genetic disease," said Howard Jonas, Chief Executive Officer, Executive Chairman and Chair
- SECSEC Form 25-NSE filed by Rafael Holdings Inc.25-NSE - Rafael Holdings, Inc. (0001713863) (Subject)
- SECRafael Holdings Inc. filed SEC Form 8-K: Other Events8-K - Rafael Holdings, Inc. (0001713863) (Filer)
- SECSEC Form DEF 14A filed by Rafael Holdings Inc.DEF 14A - Rafael Holdings, Inc. (0001713863) (Filer)
- INSIDERNew insider Grayson Alan claimed no ownership of stock in the company (SEC Form 3)3 - Rafael Holdings, Inc. (0001713863) (Issuer)
- SECSEC Form 10-K filed by Rafael Holdings Inc.10-K - Rafael Holdings, Inc. (0001713863) (Filer)